<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849770</url>
  </required_header>
  <id_info>
    <org_study_id>43708-A</org_study_id>
    <nct_id>NCT01849770</nct_id>
  </id_info>
  <brief_title>Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)</brief_title>
  <acronym>MX-ALS-001</acronym>
  <official_title>A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to find out if mexiletine is safe and effective in people
      with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either
      300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo
      (non-active study drug). The safety and efficacy of these doses will be compared to see if
      one dose is better than the other.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily motor
      neurons, for which treatment designed to slow or arrest progression remains lacking.
      Mexiletine is a use-dependent sodium channel blocker that has been FDA-approved for decades
      for the treatment of cardiac arrhythmias and more recently to treat neuropathic pain in
      diabetic polyneuropathy. Mexiletine has been shown also to be protective of neurons following
      spinal cord, head injury, and cerebral ischemia, largely by blocking excitotoxicity. Based on
      previous studies, mexiletine appears to penetrate into the central nervous system at
      concentrations sufficient to confer significant protection. Recent unpublished studies in the
      laboratory of Dr. Robert Brown at the University of Massachusetts have also demonstrated that
      mexiletine ingestion in mice genetically engineered to express high levels of mutant
      cytosolic copper-zinc superoxide dismutase-1 (SOD1) transgene prolongs survival in these
      animals. As mexiletine already has FDA-approval as an anti-arrhythmic agent, much is known
      about the pharmacology and safety of this drug in non-ALS patients. We anticipate that by
      excluding subjects with a known history of cardiac disease and with the known neuroprotectant
      properties of this medication, mexiletine is a good choice for further study in an ALS
      clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Discontinued Study Drug</measure>
    <time_frame>Screening, Baseline Visit Pre-Dose and Post-Dose, Weeks 2, 6, and 12, and at the Final Safety Visit, if a subject discontinues study drug early. Adverse Events will be assessed via telephone Weeks 1, 10, and 16.</time_frame>
    <description>Information on adverse effects of mexiletine will be determined at each visit by direct questioning of the subjects, clinical examination, review of concomitant medications, vital signs and laboratory test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration (Cmin) of Mexiletine</measure>
    <time_frame>Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6)</time_frame>
    <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Mexiletine</measure>
    <time_frame>Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6)</time_frame>
    <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.</measure>
    <time_frame>Week 6 Visit (up to 6 hours post dose)</time_frame>
    <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cerebrospinal Fluid (CSF)/Plasma Ratio</measure>
    <time_frame>Week 6 Visit (up to 6 hours post dose)</time_frame>
    <description>The concentrations of Mexiletine were measured in cerebrospinal fluid (CSF) and plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Cramp Frequency</measure>
    <time_frame>Week 3-12, post titration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Pain Severity</measure>
    <time_frame>Weeks 3-12, post titration of study medication</time_frame>
    <description>At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.
Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12</measure>
    <time_frame>Week 3-12, post titration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12</measure>
    <time_frame>Week 3-12, post titration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Severity</measure>
    <time_frame>Weeks 3-12, post titration of study medication</time_frame>
    <description>At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.
Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12</measure>
    <time_frame>Week 3-12, post titration of study medication</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in ALS Functional Rating Scale- Revised (ALSFRS-R) Score</measure>
    <time_frame>Week 0, Week 2, Week 6, Week 12 (or Early Termination Date), and Week 16</time_frame>
    <description>The ALSFRS-R is a quickly administered (5 minutes) ordinal rating scale (ratings 0-4) used to determine subjects' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, was closely associated with quality of life measures, and predicted survival.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Slow Vital Capacity (SVC) Score</measure>
    <time_frame>Week 0, Week 6, and Week 12 (or Early Termination Date)</time_frame>
    <description>The vital capacity (VC) (percent of predicted normal) will be determined, using the slow VC method. The SVC can be measured using conventional spirometers that have had a calibration check prior to subject testing. A printout from the spirometer of all SVC trials will be retained.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Sporadic Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mexiletine, 300 milligrams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mexiletine, 900 milligrams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, by mouth per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mexiletine</intervention_name>
    <arm_group_label>Mexiletine, 300 milligrams</arm_group_label>
    <arm_group_label>Mexiletine, 900 milligrams</arm_group_label>
    <other_name>Mexitil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sporadic Amyotrophic Lateral Sclerosis (SALS) diagnosed as possible,
             laboratory-supported probable, probable, or definite ALS as defined by revised El
             Escorial criteria.

          -  Age 18 years or older.

          -  Disease duration ≤ 36 months from ALS symptom onset.

          -  Capable of providing informed consent and following trial procedures.

          -  Subjects must not have taken riluzole for at least 30 days or be on a 50 milligrams
             twice daily dose of riluzole for at least 60 days prior to randomization
             (riluzole-naïve subjects are permitted in the study).

          -  Subjects must not have taken medication for muscle cramping such as cyclobenzaprine,
             baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to randomization
             or be on a stable dose for at least 60 days prior to randomization.

          -  Geographic accessibility to the site.

          -  Women must not become pregnant for the duration of the study and must be willing to
             use two contraceptive therapies and have a negative pregnancy test throughout the
             course of the study.

          -  Slow vital capacity (SVC) measure greater than or equal to 50% of predicted for
             gender, height, and age at the screening visit.

          -  Subjects medically able to undergo lumbar puncture (LP) as determined by the
             investigator (for example, no bleeding disorder, allergy to local anesthetics, a skin
             infection at or near the LP site, or evidence of high intracranial pressure).

          -  Must be able to swallow capsules throughout the course of the study, according to
             Principal Investigator (PI) judgment.

          -  Must have a caregiver assist with dispensing the study drug.

        Exclusion Criteria:

          -  Invasive ventilator dependence, such as tracheostomy.

          -  Creatinine level greater than 1.5 milligram/deciliter.

          -  Serum glutamic oxaloacetic transaminase or (aspartate transaminase) / serum glutamic
             pyruvic transaminase (alanine aminotransferase) greater than 3 times the upper limit
             of normal at screening.

          -  History of known sensitivity or intolerability to mexiletine or lidocaine.

          -  Any history of either substance abuse within the past year, unstable psychiatric
             disease, cognitive impairment, or dementia.

          -  Clinically significant conduction abnormalities on electrocardiogram or a known
             history of cardiac arrhythmia.

          -  Known history of epilepsy.

          -  Known history of congestive heart failure (CHF) or history of myocardial infarction
             within the past 24 months.

          -  Use of mexiletine for 60 days prior to Baseline Visit.

          -  Exposure to any other experimental agent (off-label use or investigational) including
             high dose creatine (greater than 10 grams a day) within 30 days prior to Baseline
             Visit.

          -  Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine.

          -  Pregnant women or women currently breastfeeding.

          -  Placement of Diaphragm Pacing System (DPS) device less than 60 days prior to Baseline
             Visit.

          -  Planned DPS device implantation after Baseline Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA, Neuromuscular Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts (Worcester) Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8897</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alsconsortium.org/</url>
    <description>Northeast ALS Consortium Website</description>
  </link>
  <link>
    <url>http://alsn.mda.org/news/multicenter-trial-test-safety-mexiletine-sporadic-als</url>
    <description>Muscular Dystrophy Association (MDA) Website</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <results_first_submitted>July 7, 2015</results_first_submitted>
  <results_first_submitted_qc>September 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2015</results_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Michael D Weiss</investigator_full_name>
    <investigator_title>Associate Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>SALS</keyword>
  <keyword>Mexiletine</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mexiletine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject in the study was enrolled July 23, 2013. Subjects were recruited and seen at Amyotrophic Lateral Sclerosis (ALS) clinics at 10 sites across the United States (U.S.).</recruitment_details>
      <pre_assignment_details>Seventy-five (75) subjects signed the consent form and were considered enrolled in the study. Fifteen (15) subjects did not meet eligibility criteria and were considered screen failures. Sixty (60) subjects were randomized to one of three treatment arms. One (1) subject was randomized to the 900mg group but never started study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mexiletine, 300 Milligrams</title>
          <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
        </group>
        <group group_id="P2">
          <title>Mexiletine, 900 Milligrams</title>
          <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mexiletine, 300 Milligrams</title>
          <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
        </group>
        <group group_id="B2">
          <title>Mexiletine, 900 Milligrams</title>
          <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="7.1"/>
                    <measurement group_id="B2" value="58.0" spread="10.7"/>
                    <measurement group_id="B3" value="57.0" spread="7.0"/>
                    <measurement group_id="B4" value="58.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months Since Symptom Onset</title>
          <description>Number of months since ALS symptom onset prior to enrolling into this study.</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="10.3"/>
                    <measurement group_id="B2" value="18.6" spread="9.2"/>
                    <measurement group_id="B3" value="17.5" spread="8.3"/>
                    <measurement group_id="B4" value="19.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months Since Diagnosis</title>
          <description>Number of months since enrolling into the study that a subject was diagnosed with ALS.</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="7.7"/>
                    <measurement group_id="B2" value="8.9" spread="8.2"/>
                    <measurement group_id="B3" value="7.3" spread="5.9"/>
                    <measurement group_id="B4" value="8.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Slow Vital Capacity (Max % predicted)</title>
          <units>Max %-predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.7" spread="19.1"/>
                    <measurement group_id="B2" value="86.2" spread="23.7"/>
                    <measurement group_id="B3" value="83.7" spread="22.6"/>
                    <measurement group_id="B4" value="85.6" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) (kg/m^2)</title>
          <units>kilograms (kg)/meter squared (m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="5.1"/>
                    <measurement group_id="B2" value="27.3" spread="4.1"/>
                    <measurement group_id="B3" value="27.1" spread="3.3"/>
                    <measurement group_id="B4" value="27.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cramps in Previous 24 hours</title>
          <units>Number of Cramps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.97" spread="3.06"/>
                    <measurement group_id="B2" value="1.68" spread="1.63"/>
                    <measurement group_id="B3" value="2.15" spread="2.13"/>
                    <measurement group_id="B4" value="1.94" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cramps in Previous 30 Days</title>
          <units>Number of Cramps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="91.0"/>
                    <measurement group_id="B2" value="29.1" spread="43.9"/>
                    <measurement group_id="B3" value="46.2" spread="55.9"/>
                    <measurement group_id="B4" value="42.8" spread="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Cramp Pain in Previous 24 hours</title>
          <description>Cramp pain measured at 0 no pain and 10 is worst pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.75" spread="2.24"/>
                    <measurement group_id="B2" value="2.32" spread="2.11"/>
                    <measurement group_id="B3" value="2.55" spread="2.78"/>
                    <measurement group_id="B4" value="2.20" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Cramp Pain in Previous 30 Days</title>
          <description>Cramp pain measured at 0 no pain and 10 is worst pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.00" spread="2.38"/>
                    <measurement group_id="B2" value="3.37" spread="2.36"/>
                    <measurement group_id="B3" value="3.35" spread="2.70"/>
                    <measurement group_id="B4" value="3.24" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALSFRS-R Total Score</title>
          <description>ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score at Baseline. Scale is measured from 0 (worst score) to 48 points (best score).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="7.8"/>
                    <measurement group_id="B2" value="33.6" spread="6.7"/>
                    <measurement group_id="B3" value="34.9" spread="5.5"/>
                    <measurement group_id="B4" value="35.0" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Discontinued Study Drug</title>
        <description>Information on adverse effects of mexiletine will be determined at each visit by direct questioning of the subjects, clinical examination, review of concomitant medications, vital signs and laboratory test results.</description>
        <time_frame>Screening, Baseline Visit Pre-Dose and Post-Dose, Weeks 2, 6, and 12, and at the Final Safety Visit, if a subject discontinues study drug early. Adverse Events will be assessed via telephone Weeks 1, 10, and 16.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Discontinued Study Drug</title>
          <description>Information on adverse effects of mexiletine will be determined at each visit by direct questioning of the subjects, clinical examination, review of concomitant medications, vital signs and laboratory test results.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentration (Cmin) of Mexiletine</title>
        <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
        <time_frame>Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration (Cmin) of Mexiletine</title>
          <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.15"/>
                    <measurement group_id="O2" value="0.68" spread="0.38"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Cmax) of Mexiletine</title>
        <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
        <time_frame>Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of Mexiletine</title>
          <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.19"/>
                    <measurement group_id="O2" value="1.27" spread="0.67"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.</title>
        <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
        <time_frame>Week 6 Visit (up to 6 hours post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.</title>
          <description>Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit.</description>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="1.08"/>
                    <measurement group_id="O2" value="6.24" spread="3.18"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cerebrospinal Fluid (CSF)/Plasma Ratio</title>
        <description>The concentrations of Mexiletine were measured in cerebrospinal fluid (CSF) and plasma.</description>
        <time_frame>Week 6 Visit (up to 6 hours post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cerebrospinal Fluid (CSF)/Plasma Ratio</title>
          <description>The concentrations of Mexiletine were measured in cerebrospinal fluid (CSF) and plasma.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.15"/>
                    <measurement group_id="O2" value="0.46" spread="0.20"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Cramp Frequency</title>
        <time_frame>Week 3-12, post titration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Cramp Frequency</title>
          <units>cramps/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.785" lower_limit="0.304" upper_limit="2.023"/>
                    <measurement group_id="O2" value="0.231" lower_limit="0.125" upper_limit="1.250"/>
                    <measurement group_id="O3" value="2.505" lower_limit="1.030" upper_limit="6.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10+cramps previous 30 days at Baseline n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.898" lower_limit="0.494" upper_limit="7.288"/>
                    <measurement group_id="O2" value="0.595" lower_limit="0.112" upper_limit="3.153"/>
                    <measurement group_id="O3" value="8.563" lower_limit="3.217" upper_limit="22.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in ALS Functional Rating Scale- Revised (ALSFRS-R) Score</title>
        <description>The ALSFRS-R is a quickly administered (5 minutes) ordinal rating scale (ratings 0-4) used to determine subjects' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, was closely associated with quality of life measures, and predicted survival.</description>
        <time_frame>Week 0, Week 2, Week 6, Week 12 (or Early Termination Date), and Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ALS Functional Rating Scale- Revised (ALSFRS-R) Score</title>
          <description>The ALSFRS-R is a quickly administered (5 minutes) ordinal rating scale (ratings 0-4) used to determine subjects' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, was closely associated with quality of life measures, and predicted survival.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.21" lower_limit="32.9" upper_limit="37.5"/>
                    <measurement group_id="O2" value="35.21" lower_limit="32.9" upper_limit="37.5"/>
                    <measurement group_id="O3" value="35.21" lower_limit="32.9" upper_limit="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.14" lower_limit="32.7" upper_limit="37.6"/>
                    <measurement group_id="O2" value="34.58" lower_limit="32.0" upper_limit="37.1"/>
                    <measurement group_id="O3" value="35.47" lower_limit="33.0" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.72" lower_limit="33.1" upper_limit="38.3"/>
                    <measurement group_id="O2" value="33.08" lower_limit="30.4" upper_limit="35.8"/>
                    <measurement group_id="O3" value="34.25" lower_limit="31.7" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="30.4" upper_limit="36.3"/>
                    <measurement group_id="O2" value="31.85" lower_limit="28.6" upper_limit="35.1"/>
                    <measurement group_id="O3" value="33.48" lower_limit="30.5" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.44" lower_limit="29.2" upper_limit="35.7"/>
                    <measurement group_id="O2" value="31.94" lower_limit="28.2" upper_limit="35.6"/>
                    <measurement group_id="O3" value="32.96" lower_limit="29.7" upper_limit="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.561</p_value>
            <method>Random slopes model</method>
            <param_type>Slope</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>Random slopes model</method>
            <param_type>Slope</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Slow Vital Capacity (SVC) Score</title>
        <description>The vital capacity (VC) (percent of predicted normal) will be determined, using the slow VC method. The SVC can be measured using conventional spirometers that have had a calibration check prior to subject testing. A printout from the spirometer of all SVC trials will be retained.</description>
        <time_frame>Week 0, Week 6, and Week 12 (or Early Termination Date)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Slow Vital Capacity (SVC) Score</title>
          <description>The vital capacity (VC) (percent of predicted normal) will be determined, using the slow VC method. The SVC can be measured using conventional spirometers that have had a calibration check prior to subject testing. A printout from the spirometer of all SVC trials will be retained.</description>
          <units>percent of predicted normal</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.74" lower_limit="80.0" upper_limit="95.5"/>
                    <measurement group_id="O2" value="87.74" lower_limit="80.0" upper_limit="95.5"/>
                    <measurement group_id="O3" value="87.74" lower_limit="80.0" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.51" lower_limit="78.1" upper_limit="94.9"/>
                    <measurement group_id="O2" value="82.92" lower_limit="73.9" upper_limit="91.9"/>
                    <measurement group_id="O3" value="84.79" lower_limit="76.3" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.98" lower_limit="75.1" upper_limit="92.8"/>
                    <measurement group_id="O2" value="77.18" lower_limit="67.0" upper_limit="87.4"/>
                    <measurement group_id="O3" value="79.58" lower_limit="70.7" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>Random slopes model</method>
            <param_type>Slope</param_type>
            <param_value>1.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>4.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>Random slopes model</method>
            <param_type>Slope</param_type>
            <param_value>-0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Pain Severity</title>
        <description>At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.
Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily.</description>
        <time_frame>Weeks 3-12, post titration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Pain Severity</title>
          <description>At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.
Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.738" lower_limit="0.364" upper_limit="1.494"/>
                    <measurement group_id="O2" value="0.340" lower_limit="0.117" upper_limit="0.986"/>
                    <measurement group_id="O3" value="0.939" lower_limit="0.466" upper_limit="1.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10+cramps previous 30 days at Baseline n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.348" lower_limit="0.616" upper_limit="2.953"/>
                    <measurement group_id="O2" value="0.572" lower_limit="0.176" upper_limit="1.859"/>
                    <measurement group_id="O3" value="2.033" lower_limit="1.123" upper_limit="3.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12</title>
        <time_frame>Week 3-12, post titration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300mg vs Placebo</title>
          </group>
          <group group_id="O2">
            <title>900mg vs Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12</title>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects n=20,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.313" lower_limit="0.100" upper_limit="0.982"/>
                    <measurement group_id="O2" value="0.158" lower_limit="0.050" upper_limit="0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10+cramps previous 30 days at Baseline n=20,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.222" lower_limit="0.079" upper_limit="0.624"/>
                    <measurement group_id="O2" value="0.069" lower_limit="0.013" upper_limit="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12</title>
        <time_frame>Week 3-12, post titration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300mg vs Placebo</title>
          </group>
          <group group_id="O2">
            <title>900mg vs Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12</title>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects n=20,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.785" lower_limit="0.342" upper_limit="1.802"/>
                    <measurement group_id="O2" value="0.361" lower_limit="0.131" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10+cramps previous 30 days at Baseline n=20,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.663" lower_limit="0.347" upper_limit="1.267"/>
                    <measurement group_id="O2" value="0.281" lower_limit="0.080" upper_limit="0.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Severity</title>
        <description>At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.
Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily.</description>
        <time_frame>Weeks 3-12, post titration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 900 Milligrams</title>
            <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Severity</title>
          <description>At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.
Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.241" lower_limit="0.115" upper_limit="0.509"/>
                    <measurement group_id="O2" value="0.136" lower_limit="0.049" upper_limit="0.379"/>
                    <measurement group_id="O3" value="0.536" lower_limit="0.275" upper_limit="1.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10+cramps previous 30 days at Baseline n=20,19,20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.467" lower_limit="0.145" upper_limit="1.504"/>
                    <measurement group_id="O2" value="0.201" lower_limit="0.050" upper_limit="0.812"/>
                    <measurement group_id="O3" value="1.248" lower_limit="0.527" upper_limit="2.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12</title>
        <time_frame>Week 3-12, post titration of study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300mg vs Placebo</title>
          </group>
          <group group_id="O2">
            <title>900mg vs Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12</title>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects n=20,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.450" lower_limit="0.183" upper_limit="1.110"/>
                    <measurement group_id="O2" value="0.254" lower_limit="0.098" upper_limit="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10+cramps previous 30 days at Baseline n=20,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.374" lower_limit="0.135" upper_limit="1.035"/>
                    <measurement group_id="O2" value="0.161" lower_limit="0.032" upper_limit="0.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mexiletine, 300 Milligrams</title>
          <description>Mexiletine, 300 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
        </group>
        <group group_id="E2">
          <title>Mexiletine, 900 Milligrams</title>
          <description>Mexiletine, 900 milligrams by mouth per day for 12 weeks.
Mexiletine</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo, by mouth per day for 12 weeks.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia Oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Salivary Hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Drug Withdrawal Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Feeling Jittery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post Lumbar Puncture Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post Procedural Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Potassium Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Pressure Diastolic Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heart Rate Irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urine Analysis Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urine Output Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle Tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sensation of Heaviness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle Contractions Involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect Lability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heat Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Epidural Blood Patch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Surgical Stapling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael D. Weiss, MD</name_or_title>
      <organization>University of Washington</organization>
      <email>mdweiss@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

